Towards the design of combination therapy for the treatment of enterovirus infections

Hendrik Jan Thibaut; Pieter Leyssen; Gerhard Puerstinger; Alexandra Muigg; Johan Neyts; Armando Mirko De Palma

doi:10.1016/j.antiviral.2011.03.187

Towards the design of combination therapy for the treatment of enterovirus infections

Hendrik Jan Thibaut
, Pieter Leyssen
, Gerhard Puerstinger
, Alexandra Muigg
, Johan Neyts
, Armando Mirko De Palma

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We report here on a comparative study of the activity of 10 enterovirus inhibitors against poliovirus 1, enterovirus 71 and human rhinovirus 14. Three of the selected molecules (Pleconaril, BTA-798 and V-073) are in clinical development. The in vitro antiviral activity of pairwise combinations of inhibitors indicated that most combinations resulted in an additive to slightly synergistic antiviral activity. However, the combination of ribavirin with a nucleoside polymerase inhibitor resulted in a pronounced antagonistic effect.

Original language	English
Pages (from-to)	213-7
Number of pages	5
Journal	Antiviral Research
Volume	90
Issue number	3
DOIs	https://doi.org/10.1016/j.antiviral.2011.03.187
Publication status	Published - Jun 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antiviral Agents
Cell Line
Drug Interactions
Drug Therapy, Combination
Enterovirus
Enterovirus Infections
Humans
Microbial Sensitivity Tests

Access to Document

10.1016/j.antiviral.2011.03.187

Cite this

@article{e27d6d5ce67f420589879164783451b1,

title = "Towards the design of combination therapy for the treatment of enterovirus infections",

abstract = "We report here on a comparative study of the activity of 10 enterovirus inhibitors against poliovirus 1, enterovirus 71 and human rhinovirus 14. Three of the selected molecules (Pleconaril, BTA-798 and V-073) are in clinical development. The in vitro antiviral activity of pairwise combinations of inhibitors indicated that most combinations resulted in an additive to slightly synergistic antiviral activity. However, the combination of ribavirin with a nucleoside polymerase inhibitor resulted in a pronounced antagonistic effect.",

keywords = "Antiviral Agents, Cell Line, Drug Interactions, Drug Therapy, Combination, Enterovirus, Enterovirus Infections, Humans, Microbial Sensitivity Tests",

author = "Thibaut, \{Hendrik Jan\} and Pieter Leyssen and Gerhard Puerstinger and Alexandra Muigg and Johan Neyts and \{De Palma\}, \{Armando Mirko\}",

year = "2011",

month = jun,

doi = "10.1016/j.antiviral.2011.03.187",

language = "English",

volume = "90",

pages = "213--7",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Towards the design of combination therapy for the treatment of enterovirus infections

AU - Thibaut, Hendrik Jan

AU - Leyssen, Pieter

AU - Puerstinger, Gerhard

AU - Muigg, Alexandra

AU - Neyts, Johan

AU - De Palma, Armando Mirko

PY - 2011/6

Y1 - 2011/6

N2 - We report here on a comparative study of the activity of 10 enterovirus inhibitors against poliovirus 1, enterovirus 71 and human rhinovirus 14. Three of the selected molecules (Pleconaril, BTA-798 and V-073) are in clinical development. The in vitro antiviral activity of pairwise combinations of inhibitors indicated that most combinations resulted in an additive to slightly synergistic antiviral activity. However, the combination of ribavirin with a nucleoside polymerase inhibitor resulted in a pronounced antagonistic effect.

AB - We report here on a comparative study of the activity of 10 enterovirus inhibitors against poliovirus 1, enterovirus 71 and human rhinovirus 14. Three of the selected molecules (Pleconaril, BTA-798 and V-073) are in clinical development. The in vitro antiviral activity of pairwise combinations of inhibitors indicated that most combinations resulted in an additive to slightly synergistic antiviral activity. However, the combination of ribavirin with a nucleoside polymerase inhibitor resulted in a pronounced antagonistic effect.

KW - Antiviral Agents

KW - Cell Line

KW - Drug Interactions

KW - Drug Therapy, Combination

KW - Enterovirus

KW - Enterovirus Infections

KW - Humans

KW - Microbial Sensitivity Tests

U2 - 10.1016/j.antiviral.2011.03.187

DO - 10.1016/j.antiviral.2011.03.187

M3 - Article

C2 - 21466823

SN - 0166-3542

VL - 90

SP - 213

EP - 217

JO - Antiviral Research

JF - Antiviral Research

IS - 3

ER -

Towards the design of combination therapy for the treatment of enterovirus infections

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this